Triple-positive breast carcinoma
MONDO:0700078A breast carcinoma which is positive for expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2).
Also known as: HR-positive HER2 positive breast cancer, hormone receptor positive her2 positive breast cancer, triple positive breast cancer
2837 clinical trials for this condition and its sub-types, 33 tagged with Triple-positive breast carcinoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
Can a Two-Drug combo outsmart Treatment-Resistant breast cancer?
Disease control OngoingResearchers are testing two experimental oral drugs, PF-07220060 and PF-07104091, combined with standard hormone therapy in people with advanced breast cancer and other solid tumors. The trial has two parts: one that finds the safest dose and another that tests the combination in…
Phase 1/2 • Sponsor: Pfizer • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New drug combo shows promise for Hard-to-Treat cancers
Disease control OngoingThis study tests a new drug called PF-07220060 in people with advanced solid tumors, including breast, prostate, lung, and liposarcoma cancers. The drug is given alone or with hormone therapies to see if it is safe and works. About 362 participants will take part to find the best…
Phase 2 • Sponsor: Pfizer • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
New combo therapy aims to slow advanced breast cancer growth
Disease control OngoingThis study tests whether adding the drug giredestrant to standard treatment (Phesgo) can help people with advanced HER2-positive, estrogen receptor-positive breast cancer live longer without their cancer getting worse. About 922 participants who have not had prior treatment for a…
Phase 3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
New oral drug aims to tackle Hormone-Driven cancers
Disease control OngoingThis study tests an experimental drug, imlunestrant, in people with advanced or metastatic breast cancer that is estrogen-receptor positive (ER+), as well as certain other cancers like endometrial cancer. The drug is given alone or combined with other anticancer therapies. The ma…
Phase 1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New combo shot aims to stop early breast cancer from returning
Disease control OngoingThis Phase 2 trial is testing whether a combination of two targeted drugs (trastuzumab and pertuzumab) given as a single shot under the skin, along with standard hormone therapy, can prevent cancer from returning after surgery in people with early-stage, hormone receptor-positive…
Phase 2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New drug cocktail shows promise in slowing HER2-Positive breast cancer
Disease control OngoingThis phase 3 trial tests whether adding the drug palbociclib to standard anti-HER2 therapy and hormone therapy can help people with HR+/HER2+ metastatic breast cancer live longer without their cancer getting worse. About 518 participants who have already received initial treatmen…
Phase 3 • Sponsor: Alliance Foundation Trials, LLC. • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC